

# Patient-Reported Outcome Measures for Symptom Perception During a Cystic Fibrosis Exacerbation

Gabriela Schmid-Mohler MSN RN, Ann-Louise Caress PhD RGN RHV, Rebecca Spirig PhD RN, Christian Benden MD, and Janelle Yorke PhD MRes

**BACKGROUND:** Symptom burden increases during pulmonary exacerbations of cystic fibrosis (CF), and patient-reported outcome measures (PROMs) are often used to evaluate symptoms as either primary or secondary outcomes. However, there is currently no guidance on the use of PROMs to assess symptom burden during pulmonary exacerbations. **METHODS:** A systematic literature search was conducted to identify PROMs measuring symptom experience, management, or influencing factors, which were developed for CF patients and had been used at least once during pulmonary exacerbations. The PROMs included were assessed for relevance and psychometrics, according to the criteria of the United States FDA guideline and the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) checklist. **RESULTS:** Five PROMs were identified, all measuring symptom perception. The CF Respiratory Symptom Diary (CFRSD) and the Symptom Scoring System were developed to assess symptom severity during pulmonary exacerbations. Of the other 3, which also included symptom scores of 2 quality of life measures, one assessed symptom severity exclusively, and 2 measured symptom severity in addition to other dimensions (such as symptom distress). All 5 instruments measured respiratory symptoms. Other relevant symptoms, such as energy and emotions, were covered by 4 instruments; pain and gastrointestinal symptoms were covered by 2 measures. All of the instruments demonstrated good internal consistency and sensitivity to change over a period up to 4 weeks. The symptom scores of the 2 quality of life measures with longer recall periods are not suitable for measuring assessed changes in a period of < 2 weeks. Criterion validity for gastrointestinal subscores has not been established. Discriminant validity was established in all of the instruments reviewed except for the Symptom Score System. **CONCLUSIONS:** Of the current PROMs used during CF pulmonary exacerbations, only 2 have been developed for this purpose, and only the CFRSD fulfilled all FDA guideline criteria. To date, there is no instrument that assesses exacerbation-specific symptom distress. *Key words:* patient-reported outcomes; questionnaire; exacerbation; cystic fibrosis; symptom perception; experience; symptom management. [Respir Care 2018;63(3):353–366. © 2018 Daedalus Enterprises]

## Introduction

Patient-reported outcome measures (PROMs) are widely used to support clinical decision-making in patient care<sup>1,2</sup>

and to evaluate the effects of interventions.<sup>3</sup> A PROM is defined as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or

---

Drs Caress and Yorke and Ms Schmid-Mohler are affiliated with the Division of Nursing, Midwifery and Social Work, School of Health Sciences, University of Manchester, Manchester, England. Ms Schmid-Mohler is affiliated with the Centre of Clinical Nursing Science, University Hospital Zurich, Zurich, Switzerland. Dr Spirig is affiliated with the Directorate of Nursing and Allied Health Professionals, University Hospital Zurich, Zurich, Switzerland. Dr Benden is affiliated with the Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland.

---

The authors have disclosed a relationship with the Nursing Science Foundation Switzerland.

Correspondence: Gabriela Schmid-Mohler MSN RN, Centre of Clinical Nursing Science, University Hospital Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland. E-mail: gabriela.schmid@usz.ch

DOI: 10.4187/respcare.05638

anyone else.”<sup>3</sup> PROMs play a crucial role in the assessment of symptoms, which are an individual’s subjective experience.<sup>4</sup> As experience can only be assessed by the person himself or herself, self-report by the patient is the accepted standard in symptom assessment.<sup>5</sup> Severity, frequency, and distress are the dimensions of symptom perception that are consistently recommended to be measured by PROMs.<sup>4,6</sup> In addition to symptom experience, symptom management and influencing contextual factors are other relevant concepts from a symptom-theory perspective.<sup>4,5</sup>

With regard to cystic fibrosis (CF) exacerbations, PROMs have been widely used to evaluate the effect of interventions on symptom severity, as either primary or secondary outcomes.<sup>7</sup> However, severity is only one aspect of symptom perception; symptom distress may be of equal or even greater relevance for patients.<sup>8</sup> Furthermore, symptoms<sup>9</sup> and increased treatment burden<sup>10</sup> can affect patients’ ability to undertake self-management activities, such as adherence to treatment, which may adversely affect clinical outcomes.<sup>11-13</sup>

The aim of this literature review was to identify PROMs assessing symptom experience, management, or influencing factors in CF subjects with pulmonary exacerbations, and to provide guidance as to which PROMs are most appropriate for use during exacerbations.

We used 3 review questions:

- What CF-specific measures are currently available for assessing symptom experience, symptom self-management, or influencing factors on symptom self-management during a pulmonary exacerbation?
- Which concepts do these measures assess? If assessing symptom perception, which dimensions (severity, frequency, quality, or distress) of symptom experience do these measures assess?
- What are the strengths and weaknesses of the measures available, specific to their use during pulmonary exacerbations?

## Methods

For this review, we searched systematically for articles describing PROMs that assess symptom experience (eg, perception or evaluation), symptom management (eg, adherence) or influencing factors (eg, self-efficacy) in subjects with CF who experienced pulmonary exacerbations (Table 1).

Inclusion criteria were:

- Articles published in 1994 or later, written in German or English, with measures in English or German. Measures developed before 1994 were included if used in the past 20 y. Measures not used in the past 20 y were deemed to have little relevance for current clinical practice and were therefore not included.

Table 1. Search Strategy

The MEDLINE/PUBMED, CINAHL, EMBASE/OVID SP, PSYCINFO, and ASSIA databases were searched on 29 August 2016. Two searches were performed: Search A, which was not restricted to acute phases, and Search B, which was restricted to acute phases. Search terms were:

Search A: (self-report\* OR self-administ\* OR patient-reported outcome measure OR questionnaire OR diary OR scale) AND (self-management OR self-care OR sign OR symptom) AND (cystic fibrosis)

Search B: (self-report\* OR self-administ\* OR patient-reported outcome measure OR questionnaire OR diary OR scale) AND (adherence OR compliance OR persistence OR concordance) AND (exacerbation OR intravenous therapy OR intravenous antibiotic OR acute infection) AND (cystic fibrosis)

\* indicates that all varying endings were retrieved for this search term.

- Adult sample (a portion or all of the participants > 18 y old).
- The measure had been used (at least once) during an exacerbation period.
- The measure was developed for patients with CF, in either acute or stable phases.
- The measure’s development and validation were reported, in either stable or acute phases.

One author checked 10% of the studies deemed to be relevant, and all included studies for inclusion and exclusion criteria. Two authors conducted a quality appraisal of the included studies.

Eligible PROMs were critically appraised according to criteria developed by the United States FDA, which recommends a 5-step PROM-development strategy: 1) hypothesize the conceptual framework; 2) adjust the conceptual framework and draft the measure based on patients’ input; 3) confirm the conceptual framework and assess other measurement properties; 4) collect, analyze, and interpret data; and 5) modify the measure.<sup>3</sup> These criteria were supplemented with those of the Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN), which describe a standard for high-quality methodology for studies focusing on measurement properties of PROMs. The criteria refer to reliability, content, construct, criterion validity, responsiveness, and interpretability of PROMs.<sup>14</sup>

## Results

The article selection process is described in Figure 1. A total of 107 measures were initially identified. Two meta-analyses<sup>15,16</sup> yielded adherence measures, but as their investigations did not take place during exacerbation pe-




Fig. 1. Flowchart. CF = cystic fibrosis.

riods, the original articles were not screened to identify further measures. Of the 107 measures, 89 had never been applied during an exacerbation. Of the remainder, 7 were applied during an exacerbation but were not initially developed for CF; for 6 further measures, no validation data were available.

Only 5 measures fulfilled the selection criteria. Of these, 2 were CF-specific health-related quality-of-life measures that included symptom scores: the CF Questionnaire Revised 14+ for teens and adults (CFQ-R)<sup>17</sup> and the CF Quality of Life (CFQOL) questionnaire.<sup>18</sup> Three CF-specific symptom scores were also identified: the Memorial Symptom Assessment Scale for Adults with CF (MSAS

CF);<sup>8</sup> the CF Respiratory Symptom Diary (CFRSD),<sup>19</sup> of which a short version exists, the CF Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score;<sup>20</sup> and the Symptom Score System.<sup>21</sup> All 5 measures selected assessed symptom perception.

We identified no CF-specific validated measures that assessed symptom self-management (self-management, adherence, and symptom evaluation or response, see Fig. 1) or influencing factors on symptom self-management (knowledge and self-efficacy, see Fig. 1) and had been applied during an exacerbation. The Self-Management Questionnaire for CF<sup>22</sup> and the CF Self-Care Practice Instrument<sup>23</sup> measure self-management or self-care in

adults, but neither was developed for exacerbation or had been used in such episodes. Furthermore, we identified numerous measures that assessed treatment adherence in general.<sup>13,24-38</sup> Of these, 2 studies measured adherence during an exacerbation, but they used a non-validated scale.<sup>39,40</sup> The Perceived Health Competence Scale, which assesses self-efficacy,<sup>41</sup> the Transitional Dyspnoea Index Score,<sup>42</sup> the Chronic Respiratory Disease Questionnaire,<sup>43</sup> the Pain Catastrophizing Scale,<sup>44</sup> the Brief Pain Inventory,<sup>44</sup> the Schwartz Fatigue Scale,<sup>45</sup> and the Quick Inventory of Depressive Symptomatology<sup>46</sup> were each used once during an exacerbation, but they were not developed for a CF-specific population and were therefore not included for review. Five symptom checklists had been used during an exacerbation, but no validation data were available.<sup>45,47-50</sup>

The characteristics of the 5 measures included are presented in Table 2. Their psychometrics, namely validity, reliability, responsiveness to change, and interpretability, have been assessed according to the criteria provided in the COSMIN and FDA guidelines.

All 5 selected measures were developed between 2000 and 2012. The CFQ-R and the CFQOL are CF-specific quality-of-life measures. However, their symptom scores, especially the respiratory and the digestive symptom scale of the CFQ-R, have been widely and independently used in intervention studies to evaluate treatment effects in CF. The other 3 measures are symptom scores, and while the CFRSD and the Symptom Score System were developed for exacerbations, the MSAS-CF was intended for general use.

With regard to content, respiratory symptoms are assessed in all 5 measures, energy and burdensome emotions in 4 measures, pain and gastrointestinal symptoms in 2 measures, and fever/chill in 1 measure. An overview is provided in Table 3.

The CFQ-R, the CFRSD, the Symptom Score System, and the CFQOL ask for symptoms unidimensionally in that they separately assess severity, frequency, or distress for each symptom (Table 2). Only the MSAS-CF asks for symptoms multidimensionally, indicating an assessment of all domains for each symptom. The CFQ-R, the CFRSD, and the Symptom Score System measure the severity, the frequency, or the quality of a symptom. The CFQOL assesses symptom distress, asking for “troublesomeness” and “embarrassment.” In addition to severity and frequency, the MSAS-CF asks about the distress that accompanies each symptom by asking how much “distress” or “bothersomeness” the patient associates with the symptom.

All instruments were developed on the basis of literature review, other measures, or expert opinion. Only the CFRSD, CFQ-R, and the CFQOL involved patients in the generation of content as recommended by the FDA guideline, and only the CFRSD involved patients during an exacerbation and tested items for clarity via cognitive de-

briefing interviews. In some instruments (eg, CFRSD), items that were bothersome to patients but had relatively low prevalence (eg, pain), were excluded.

Other than for the CFQ-R digestive score, the CFRSD emotional score, and the Symptom Score System, discriminant validity was established in all of the selected subscores. Criterion validity was established for the respiratory scores of the CFQ-R, the CFQOL (chest score), and Symptom Score System using FEV<sub>1</sub> values. For the respiratory scores of the CFRSD and the MSAS-CF, it was established by using other self-report measures, but not FEV<sub>1</sub> values. Emotions and energy scores of the CFQ-R, the CFQOL and the MSAS-CF were validated using other validated self-report scores as a gold standard.

For gastrointestinal-related items, no criterion validity has been established, either for the CFQ-R or for the MSAS-CF gastrointestinal scores. The MSAS-CF gastrointestinal scores correlated only weakly with the CFQ-R digestive symptom score. This is unanticipated, but could be due to the CFQ digestive symptom score, which showed an unexpected pattern in previous research.<sup>51</sup> In addition, all instruments demonstrated good internal consistency.

All measures demonstrated sensitivity to change during pulmonary exacerbation. However, because the CFQ-R, the CFRSD, and the MSAS-CF were not developed for exacerbations, they have relatively long recall periods (ie, 1 week for the MSAS-CF and 2 weeks for the CFQOL and the CRQ-R). In testing the CFRSD’s daily versus weekly recall period, the weekly scores were higher than the calculated mean score of the preceding 6 days. Significant differences were found for the mean of the five respiratory items, the 5 mood items, and the single tiredness item. These results confirm that symptom-measurement accuracy is generally higher if measured daily.<sup>60</sup> Minimal important different scores were established on the basis of statistical analysis for the CFQ-R respiratory score and the CFRSD respiratory score.

## Discussion

Five CF-specific measures that assess a symptom-specific concept and were used at least once during a pulmonary exacerbation were identified. There were 3 PROMs developed for stable phases, and 2 for exacerbations. All 5 PROMs measured symptom perception. Only the MSAS-CF, developed for stable phases, assessed severity, frequency, and distress for each symptom. The other instruments asked for severity, frequency, quality, or distress for 1 symptom. Of the 2 exacerbation-specific PROMs, the CFRSD assessed symptom severity exclusively, while the Symptom Score System assessed severity, timing, or quality of 1 symptom. With regard to content validity, all 5 instruments measured respiratory symptoms. Other relevant symptoms, such as energy and emotions, were covered

Table 2. Psychometric Properties of the PROMs Used During an Exacerbation to Assess Symptom Perception

Scale	CFQ-R 14+ Symptom Scale	CFQOL Symptom Scale	CFRSD	Symptom Score System	MSAS-CF
Characteristics					
Developers	Henry et al <sup>17</sup>	Gee et al <sup>18</sup>	Goss et al <sup>19</sup>	Jarad and Sequeiros <sup>21</sup>	Sawicki et al <sup>8</sup>
Concept measured	QOL with symptom scores	QOL with symptom scores	Symptom score for pulmonary exacerbation	Symptom score for pulmonary exacerbation	Physical and psychological symptom burden
Dimension of symptom scores	Unidimensional: severity or frequency or quality (color of sputum)	Unidimensional: distress (troublesomeness or embarrassment)	Unidimensional: severity	Unidimensional: severity, timing or quality (color and viscosity of sputum)	Multidimensional: severity, frequency and distress (distress or bothersomeness) of all symptoms
Short version	None	None	CFRSD-CRISS (respiratory items) <sup>20</sup>	None	None
Age group	> 14 y old	Adolescents and adults	Adults	Adults	Adults
Item	Symptom scores vitality (4 items), emotional functioning (5 items), respiratory symptoms (6 items), digestive symptoms (3 items)	Symptom scores chest symptoms (4 items), emotional responses (8 items)	Symptom scores respiratory symptoms (8 items), CFRSD-CRISS emotions (4 items)	Symptom scores one score including 4 items such as cough, sputum volume and viscosity, breathlessness, fatigue	Symptom scores psychological symptoms (5 items, CF PSYCH), respiratory symptoms (6 items, CF RESP), gastrointestinal symptoms (4 items, CF GI)
Scoring	Other QOL domains social functioning (6 items), role functioning (4 items), eating problems (3 items), body image (3 items), treatment burden (3 items), health perception (3 items), physical functioning (8 items), weight (1 item) <sup>51</sup>	Other QOL domains physical functioning (10 items), social functioning (4 items), treatment issues (3 items), future concerns (6 items), interpersonal relationships (10 items), body image (3 items), career issues (4 items)	Others domain activity (4 items)	NA	Seven items of the preliminary item list did not load on any factor and were not included in one of the three scores (CF RESP, CF PSYCH, CF GI). <sup>8</sup>
Development and patient involvement according to the FDA Guideline	4-point Likert-type scale	6-point Likert-type scale	Dichotomous or 3–4-point Likert-type scale	4-point Likert-type scale	4- or 5-point Likert-type scale
Development and conceptualization	Based on literature, previous QOL measures, and consultations with health care professionals and CF associations.	Based on interviews with patients, consultation with specialist staff, and relevant literature.	Not described. <sup>19</sup>	Based on the Medical Research Council Respiratory Symptom Score and the breathlessness score.	Based on the generic symptom questionnaires, the MSAS PSYCH and the MSAS PHYS, which were derived from Symptom Management Theory. <sup>52</sup>

(continued)



Table 2. Continued

Scale	CFQ-R 14+ Symptom Scale	CFQOL Symptom Scale	CFRSD	Symptom Score System	MSAS-CF
Patient involvement in identification of the content	Yes: 22 adult (> 14 y old) and 11 pediatric patients (< 14 y old) were interviewed; purposive sampling in adults was applied with mild ( $n = 1$ ), moderate ( $n = 10$ ), and severe ( $n = 11$ ) disease severity. The interview guideline was not presented. No special focus on exacerbation was applied. <sup>17</sup>	Yes: 60 CF patients > 16 y old with mean FEV <sub>1</sub> % predicted of 59% were interviewed. No further information regarding the interview process is reported. No special focus on exacerbation was applied. <sup>24</sup>	Yes: 12 adults and 13 pediatric patients were interviewed during the first 72 h of initiating treatment for pulmonary exacerbation. The Day Reconstruction Method was applied in the interview, and triggers were explored. <sup>19</sup> Items were excluded due to prevalence data in this patient group.	No	No
Patient involvement in testing the clarity of items	Yes	Yes	Yes: Cognitive interviewing techniques were used to assess the relevance and comprehensibility of the items. <sup>19</sup>	No	No
Validity and reliability according to the COSMIN criteria					
Content validity (face validity)	See section 'Development and patient involvement according to the FDA Guideline'	See section 'Development and patient involvement according to the FDA Guideline'	See section 'Development and patient involvement according to the FDA Guideline'	See section 'Development and patient involvement according to the FDA Guideline'	See section 'Development and patient involvement according to the FDA Guideline'
Criterion validity	Respiratory score established using FEV <sub>1</sub> : moderate correlation with FEV <sub>1</sub> % predicted ( $r = 0.42$ , $P$ value not reported) and weak correlation with number of intravenous antibiotic courses ( $r = -0.27$ , $P$ value not reported). <sup>51</sup>	Chest score established using FEV <sub>1</sub> : correlation with FEV <sub>1</sub> was not tested, but chest symptom scores increased significantly during intravenous therapy for pulmonary exacerbation from 47 to 70.3 in the hospital group ( $P = .006$ ), and from 49.7 to 68.8 ( $P = .03$ ) in the home group. <sup>12</sup>	Respiratory score (CFRSD-CRIS) and emotional score partly established using daily step count, but not FEV <sub>1</sub> : Step-rate was significantly higher (no overlap of the 95% CIs) in those patients who did not experience one of the following symptoms in contrast to those patients who experienced the symptom: difficulty breathing, cough, chest tightness, or feeling tired (ie, respiratory symptoms), or feeling worried, cranky, or frustrated (ie, emotional items). <sup>54</sup>	Total score established using FEV <sub>1</sub> and CFQ-R: correlation with FEV <sub>1</sub> ( $r = -0.41$ , $P < .0001$ ), the respiratory symptom score of the CFRQ <sup>55</sup> ( $r = -0.62$ , $P < .001$ ), and the total CFRQ score ( $r = -0.47$ , $P < .001$ ). <sup>21</sup>	MSAS-CF RESP score partly established using the CFQ-R scores, but not FEV <sub>1</sub> : strong correlations with the CFQ-R respiratory symptom score ( $r = -0.60$ ) and the CFQOL chest score ( $r = -0.70$ , $P < .05$ ). <sup>8</sup>

(continued)

Table 2. Continued

Scale	CFQ-R 14+ Symptom Scale	CFQOL Symptom Scale	CFRSD	Symptom Score System	MSAS-CF
Hypothesis testing Convergent validity	Emotional functioning score established using SF-36 and FEV <sub>1</sub> ; strong correlation with the SF-36 mental health score (r = 0.74, P = .01) and weak correlation FEV <sub>1</sub> % predicted (r = 0.28, P = .01). <sup>53</sup>	Emotional score established using SF-36; strong correlation with the SF-36 mental health score (r = 0.64, P < .001). <sup>18</sup>			MSAS-CF PSYCH score established using CFQ-R; strong correlation with the CFQ-R emotional functioning score (r = -0.69, P < .05). <sup>8</sup>
	Vitality score established using SF-36 and FEV <sub>1</sub> ; strong correlation with the SF-36 vitality score (r = 0.84, P = .01). <sup>53</sup> , and weak correlation with FEV <sub>1</sub> % predicted (r = 0.26, P value not reported) and the number of intravenous antibiotic courses (r = -0.25, P value not reported). <sup>51</sup>				MSAS-CF GI score had very weak correlation with the CFQ-R digestive score (r = -0.19, P < .05). <sup>8</sup>
	Digestive score was not established. <sup>51,53</sup>				
Hypothesis testing Convergent validity	Not reported.	Not reported.	Not reported.	Not reported.	MSAS-CF RESP: good: strongest correlations with respiratory symptom scores (CFQOL r = -0.70, P < .05 / CFQ-R r = -0.60, P < .05) out of all tested scores <sup>8</sup>
					MSAS-CF PSYCH: good: strongest correlation with emotional response (CFQ-R r = -0.69, P < .05) out of all tested scores <sup>8</sup>

(continued)

Table 2. Continued

Scale	CFQ-R 14+ Symptom Scale	CFQOL Symptom Scale	CFRSD	Symptom Score System	MSAS-CF
Discriminant validity	Respiratory, vitality and emotional functioning score: good Strong discriminant validity was reported in comparing visits where patients felt well to visits where they felt sick, with no overlap of the 95% CIs. Scores differed significantly between disease stages by FEV <sub>1</sub> % predicted (< 40, 40 to < 70, 70 to < 100) and showed a linear trend. <sup>51</sup> Digestive score: not established. <sup>51</sup>	Chest score: good Chest score discriminated between moderate and severe, and mild and severe disease (FEV <sub>1</sub> % predicted > 70, 40–70, < 40). <sup>18</sup>	Respiratory score (CFRSD-CRIS): good Discriminant validity of the CFRSD-CRIS was tested by comparing ill days to well days, where a significant change between health state was reported (area under the curve of ROC = 0.83, 95% CI: 0.80–0.86). <sup>20</sup>	Not reported	MSAS-CF GI: not good: strongest correlations with weight (CFQ-R $r = -0.49$ , $P < .05$ ), followed by respiratory symptoms (CFQOL $r = -0.42$ , $P < .05$ / CFQ-R $r = -0.31$ , $P < .05$ ), emotional response (CFQ-R $r = -0.35$ , $P < .05$ ), and lowest with digestive symptoms (CFQ-R $r = -0.19$ , $P < .05$ ), which was not expected <sup>8</sup> MSAS-CF RESP, MSAS-CF GI, MSAS-CF PSYCH: good Subscores of the MSAS-CF RESP, MSAS-CF GI, and MSAS-CF PSYCH were higher in patients with low FEV <sub>1</sub> % predicted < 40% ( $P < .05$ ), indicating good discriminant validity. <sup>8</sup>
Internal consistency	Respiratory, vitality and emotional functioning and digestive score: good Cronbach's alpha was 0.87 for the respiratory symptom, 0.68 for the digestive symptom, 0.80 for the vitality, and 0.77 for the emotional response scale. <sup>51</sup>	Chest and emotional score: good Cronbach's alpha for the overall questionnaire was good (range 0.72–0.92); 0.91 for the emotional response scale and 0.83 for the chest symptom scale. <sup>18</sup>	Respiratory score (CFRSD-CRIS): good Cronbach's alpha of the CFRSD-CRIS was 0.77, and the intra-class correlation coefficient using a 1-d interval was 0.79. <sup>20</sup> Emotional score was not reported.	Total score: good All four items correlated with one another ( $r > 0.38$ for all $P < .001$ for all correlations). No Cronbach's alpha was reported. <sup>21</sup>	MSAS-CF RESP, MSAS-CF GI, MSAS-CF PSYCH: good The final version of the measure demonstrated good internal consistency with Cronbach's alpha ranging from 0.74 to 0.86. <sup>8</sup>

(continued)



Table 2. Continued

Scale	CFQ-R 14+ Symptom Scale	CFQOL Symptom Scale	CFRSD	Symptom Score System	MSAS-CF
Measurement error	Not reported.	Test-retest reliability after 7–10 days was robust, with 0.90 for the emotional and 0.93 for the chest score. <sup>18</sup>	Not reported.	Not reported.	Not reported.
Responsiveness to pulmonary exacerbations	Respiratory score demonstrated (on a scale from 0–100, 100 indicating best QOL in this area): Hypertonic saline trial, in 132 hospitalized CF patients experiencing a pulmonary exacerbation: an increase from admission day to discharge of 19 (SD 21) in the intervention group and 21 (SD 18) in the control group. <sup>50</sup> Vitality, emotional functioning, and digestive score: change from nonexacerbating state to exacerbating state in emotional functioning from 90.7 to 78.0 ( $P = .008$ ), in vitality from 67.8 to 63.1 ( $P = .34$ ), and in digestion from 84.5 to 75.4 ( $P = .064$ ) <sup>56</sup>	Chest and emotional score demonstrated over a 2-week application period during pulmonary exacerbation. <sup>12</sup>	Respiratory score (CFRSD-CRISS) demonstrated (on a scale of 0–100, 100 indicating highest symptom severity): in patients treated for pulmonary exacerbation, the CFRSD-CRISS score was 47.5 (SD 11.2) at the start of treatment and 21.6 (SD 15.6) at the end of treatment. <sup>57</sup> Emotional score was not reported during exacerbation.	Total score demonstrated in 2-week treatment period with intravenous antibiotics. <sup>21</sup>	MSAS-CF RESP, MSAS-CF GI, MSAS-CF PSYCH was not reported: demonstrated only for single items during intravenous treatment of a pulmonary exacerbation. <sup>58</sup>

(continued)

Table 2. Continued

Scale	CFQ-R 14+ Symptom Scale	CFQOL Symptom Scale	CFRSD	Symptom Score System	MSAS-CF
Interpretability	Respiratory score: minimal clinically important difference is suggested on statistical analysis with a score of 4.0 for stable and 8.5 for pulmonary exacerbation over a 4-week period <sup>59</sup> Vitality, emotional functioning, and digestive score: no minimal important difference suggested.	Chest and emotional score: no minimal important difference score is suggested.	Respiratory score (CFRSD-CRISS): The minimal important difference suggested on the basis of statistical analysis is a within-group change of 11 points. A mean change of -16.5 (95% CI -13.2 to -19.7) with treatment for exacerbation was reported. <sup>20</sup> Emotional score: no minimal important difference is reported.	Total score: no minimal important difference is suggested on the basis of statistical analysis, but a minimal clinically important difference of > 1 after 2 weeks of treatment with intravenous antibiotics is suggested based on previous experience in patients with COPD <sup>21</sup>	MSAS-CF RESP, MSAS-CF GI, MSAS-CF PSYCH: no minimal important difference in scores is suggested.
Recall period	2 weeks	2 weeks	daily	actual	1 week

PROM = patient-reported outcome measure

CFQ-R 14+ = Cystic Fibrosis Questionnaire Revised 14+ for teens and adults

CFQOL Symptom Scale = Cystic Fibrosis Quality of Life

CFRSD = Cystic Fibrosis Respiratory Symptom Diary

MSAS-CF = Memorial Symptom Assessment Scale for Adults with Cystic Fibrosis

CFRSD-CRISS = Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score

QOL = quality of life

COSMIN = Consensus-Based Standards for the Selection of Health Measurement Instruments

CFRQ = Cystic Fibrosis Respiratory Questionnaire

ROC = receiver operating characteristic

by 4 instruments, with pain and gastrointestinal symptoms covered by 2 measures. All instruments demonstrated good internal consistency and sensitivity to change for up to 4 weeks. However, the symptom scores of the 2 QOL measures have a recall period of 2 weeks, making them unsuitable for measuring change during exacerbation periods of < 2 weeks. Criterion validity has been established for most respiratory, emotional, and energy scores, but not for gastrointestinal scores.

One critical issue is that CF subjects were only involved in the development of the CFQ, the CFQOL, and the CFRSD, and only the CFRSD involved subjects in testing the clarity of its items. The lack of patient involvement in developing certain measures gives rise to the question of whether the content validity of those instruments is actually given. Only 1 measure's tool development (CFRSD) included interviews with subjects experiencing a pulmonary exacerbation. However, subjects were interviewed only at the start of the exacerbation, coinciding with the time when all prevalence-based decisions were being made regarding the inclusion of items. This may be a critical issue regarding the instrument's content validity, as certain symptoms may develop in response to other symptoms or to treatment during an exacerbation. For example, pain due to coughing, lack of muscle strength due to lack of physical activity, and weight loss due to lack of appetite have been reported as relevant symptoms during pulmonary exacerbations from the patient's perspective.<sup>9,61</sup> The role of gastrointestinal symptoms with regard to exacerbations must also be clarified. Although diarrhea and nausea are frequently reported adverse effects of antibiotic treatment, which is a common treatment of pulmonary exacerbation in CF, their relevance for patients in the course of the exacerbation is not clear at this time. To explore the evolution of symptoms over time and to minimize recall bias, a recurring qualitative measure design with several interview time points should be applied in future research.<sup>62</sup>

The CFRSD, CFQ-R, and the Symptom Score System measure symptom severity. Similar to the CFRSD, the Exacerbations of Chronic Pulmonary Disease Tool, an instrument measuring the effect of treatment on exacerbation in COPD, assesses symptom severity and frequency but not symptom distress.<sup>63,64</sup> PROMs that assess symptom severity and frequency may be suitable for detecting and assessing the severity of an exacerbation in CF and COPD. However, the limitations of these symptom dimensions (severity and frequency) may make these instruments less suitable for guiding and evaluating patients' symptom management. Given that symptom distress is a driver in patient self-management, inclusion of the distress dimension in symptom assessment is essential in the planning and evaluating of interventions, especially in terms of self-management.<sup>4</sup> This is especially relevant in CF, as earlier research emphasizes that CF subjects perceive symptom

Table 3. Content Covered by the Measures

Scale	CFQ-R 14+ Symptom Scale	CFQOL Symptom Scale	CFRSD	Symptom Score System	MSAS-CF
Respiratory	Respiratory symptoms: coughing, waking due to cough, mucus, breathlessness, congestion, wheezing	Chest symptoms: coughing, breathlessness	Respiratory items: cough, mucus, breathlessness, tightness, wheeze	Respiratory: cough sputum, breathlessness	Respiratory: cough, breathlessness, sinus discharge
Energy	Vitality: tired, exhausted, top form, full of energy	NA	Respiratory score: tired	Fatigue	Respiratory: difficulty sleeping, lack of energy
Emotions	Emotional functioning: worry, sadness/depression, loneliness	Emotional response: anxiety, sadness/depression anger, frustration, irritability	Emotional items: worry, sadness/depression, frustration, irritability	NA	Psychological symptoms: worry, sadness, irritability, nervousness, difficulty concentrating
Pain	Digestive symptoms: abdominal pain	NA	NA	NA	Respiratory: pain
Gastrointestinal	Digestive symptoms: wind, diarrhea, abdominal pain, weight	NA	NA	NA	Gastrointestinal symptoms: loss of appetite, weight loss, vomiting, nausea
Fever, chill	NA	NA	Respiratory items: fever, chill	NA	NA

CFQ-R 14+ = Cystic Fibrosis Questionnaire Revised 14+ for teens and adults

CFQOL Symptom Scale = Cystic Fibrosis Quality of Life

CFRSD = Cystic Fibrosis Respiratory Symptom Diary

MSAS-CF = Memorial Symptom Assessment Scale for Adults with Cystic Fibrosis

NA = not applicable

severity and distress as different dimensions.<sup>8</sup> Still, it remains unclear whether symptom severity truly reflects a dimension of importance for patients. This must be discussed critically in future research. Regardless, future developers of PROMs in CF will have to consider how to include the dimension of symptom distress in instrument development, along with how “distress” should be measured and how to formulate appropriately inclusive wording. To date, the 2 CF PROMs that assess symptom distress use different wording: where the CFQOL assesses distress as “troublesomeness” and “embarrassment,” the MSAS-CF assesses “distress” or “bothersomeness.” The lack of standardized wording for symptom distress in CF PROMs may distort the comparability of symptom distress between the different measures. Research from other populations with long-term conditions indicates that subjects experience symptoms that interfere with normality and daily life as burdensome, which could be a dimension of symptom distress for CF patients as well.<sup>65</sup> The matter of which symptom characteristics lead to distressing exacerbation experiences remains to be explored.

Of the instruments in question, only the CFRSD covered all aspects of the FDA guidance and was developed specifically for use in exacerbations. It is currently held to be the most appropriate instrument for assessing symptom perception during a pulmonary exacerbation. However, a critical issue in the development of the CFRSD is that items were derived from patient narratives at the beginning of the exacerbations. There is a lack of knowledge about how patients experience symptoms during exacerbation. This means that there is currently no definitive answer as to whether the CFRSD incorporates all relevant symptoms over the course of the exacerbation. One limitation is that it assesses only symptom severity, although symptom distress may be a further relevant dimension.

A limitation of this review is that the content that should be covered by a PROM was not able to be defined from the patient perspective. This is due to the current lack of qualitative data regarding CF patients’ experience of a pulmonary exacerbation. In the review, we addressed this limitation by appraising whether a PROM development involved patients.

Future research must explore patients’ experience of an exacerbation, preferably using a longitudinal design. Additionally, symptom distress in CF requires further conceptualization. This knowledge will provide a basis for the development of a PROM to assess symptom distress during pulmonary exacerbation.

## Conclusion

Of the 5 PROMs that were included in this review, only the CFRSD fulfilled all the criteria of the FDA PROM development guidelines and was developed for pulmonary

exacerbations. However, because items for the PROM were derived from patient data at the beginning of exacerbations, this may be a critical issue for content validity in the CFRSD. A limitation of the CFRSD is that it assesses only symptom severity. Because evidence indicates that symptom distress is a relevant concept from the patient’s point of view, PROMs including such a dimension are needed. Further research should explore patients’ experience of pulmonary exacerbation and provide a basis for conceptualizing the symptom distress associated with pulmonary exacerbation.

## ACKNOWLEDGMENTS

We thank Chris Shultis de Windter and Jane White for editing assistance.

## REFERENCES

1. Higginson IJ, Carr AJ. Measuring quality of life: Using quality of life measures in the clinical setting. *BMJ* 2001;322(7297):1297-1300.
2. World Health Organisation. Division of Mental Health and Prevention of Substance Abuse. WHOQOL: Measuring Quality of Life. Geneva : World Health Organization, 1997. <http://www.who.int/iris/handle/10665/63482>.
3. U.S. Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Federal Register. 2009. [www.fda.gov/downloads/drugs/guidances/ucm193282.pdf](http://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf).
4. Humphreys J, Janson S, Donesky D, Faucett J, Aouizerat B, Miaskowski C, et al. Theory of symptom management. In: Smith MJ, Liehr PR, eds. *Middle Range Theory for Nursing*. New York: Springer Publishing Company, 2014.
5. Dodd M, Janson S, Facione N, Faucett J, Froelicher ES, Humphreys J, et al. Advancing the science of symptom management. *J Adv Nurs* 2001;33(5):668-676.
6. Chang VT, Hwang SS, Thaler HT, Kasimis BS, Portenoy RK. Memorial symptom assessment scale. *Expert Rev Pharmacoecon Outcomes Res* 2004;4(2):171-178.
7. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. *Proc Am Thorac Soc* 2007;4(4):378-386.
8. Sawicki GS, Sellers DE, Robinson WM. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. *J Pain Symptom Manage* 2008;35(4):372-380.
9. Abbott J, Holt A, Hart A, Morton AM, MacDougall L, Pogson M, et al. What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis. *J Cyst Fibros* 2009;8(5):356-359.
10. Balaguer A, Gonzalez de Dios J. Home versus hospital intravenous antibiotic therapy for cystic fibrosis. *Cochrane Database Syst Rev* 2012;3:CD001917.
11. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. *Pediatr Pulmonol* 2012;47(6):523-533.
12. Esmond G, Butler M, McCormack AM. Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. *J Clin Nurs* 2006;15(1):52-60.
13. Abbott J, Havermans T, Hart A. Adherence to the medical regimen: Clinical implications of new findings. *Curr Opin Pulm Med* 2009;15(6):597-603.
14. Mokkink LB, Prinsen CA, Bouter LM, Vet HC, Terwee CB. The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument. *Braz J Phys Ther* 2016;20(2):105-113.

15. Glasscoe CA, Quittner AL. Psychological interventions for people with cystic fibrosis and their families. *Cochrane Database Syst Rev* 2008(3):CD003148.
16. Main E, Prasad A, Schans C. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. *Cochrane Database Syst Rev* 2005(1):CD002011.
17. Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. *Qual Life Res* 2003;12(1):63-76.
18. Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. *Thorax* 2000;55(11):946-954.
19. Goss CH, Edwards TC, Ramsey BW, Aitken ML, Patrick DL. Patient-reported respiratory symptoms in cystic fibrosis. *J Cyst Fibros* 2009;8(4):245-252.
20. Goss CH, Caldwell E, Gries KS, Leidy NK, Edwards T, Flume PA, et al. Validation of a novel patient-reported respiratory symptoms instrument in cystic fibrosis: CFRSD-CRISS. *Pediatr Pulmonol* 2013;48:295-296.
21. Jarad NA, Sequeiros IM. A novel respiratory symptom scoring system for CF pulmonary exacerbations. *QJM* 2012;105(2):137-143.
22. Bartholomew LK, Czyzewski DI, Parcel GS, Swank PR, Sockrider MM, Mariotto MJ, et al. Self-management of cystic fibrosis: short-term outcomes of the cystic fibrosis family education program. *Health Educ Behav* 1997;24(5):652-666.
23. Baker LK, Denyes MJ. Predictors of self-care in adolescents with cystic fibrosis: a test of Orem's theories of self-care and self-care deficit. *J Pediatr Nurs* 2008;23(1):37-48.
24. Abbott J, Dodd M, Gee L, Webb K. Ways of coping with cystic fibrosis: implications for treatment adherence. *Disabil Rehabil* 2001;23(8):315-324.
25. Arias Llorente RP, Bousoño Garcia C, Diaz Martin JJ. Treatment compliance in children and adults with cystic fibrosis. *J Cyst Fibros* 2008;7(5):359-367.
26. Dalcin Pde T, Rampon G, Pasin LR, Becker SC, Ramon GM, Oliveira VZ. Perception of disease severity in adult patients with cystic fibrosis. *J Bras Pneumol* 2009;35(1):27-34.
27. Flores JS, Teixeira FA, Rovedder PM, Ziegler B, Dalcin Pde T. Adherence to airway clearance therapies by adult cystic fibrosis patients. *Resp Care* 2013;58(2):279-285.
28. Ros M, Casciaro R, Luca F, Troiani P, Saloni E, Favilli F, et al. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. *J Aerosol Med Pulm Drug Deliv* 2014;27(2):133-137.
29. Burrows JA, Bunting JP, Masel PJ, Bell SC. Nebulised dornase alpha: adherence in adults with cystic fibrosis. *J Cyst Fibros* 2002;1(4):255-259.
30. Patterson JM, Wall M, Berge J, Milla C. Gender differences in treatment adherence among youth with cystic fibrosis: development of a new questionnaire. *J Cyst Fibros* 2008;7(2):154-164.
31. Simonton S, Sherman AC, Campbell D, Reddy RM, Kumar S, O'Brien CE, et al. Adherence to airway clearance therapy among adults with cystic fibrosis. *Pediatr Pulmonol* 2011;46:406.
32. Braithwaite M, Clarke D, Sofianopoulos S, Dooley M, Finlayson F, Liew D, et al. Personality, psychosocial factors and illness effect on adherence behaviour in cystic fibrosis (CF). *J Cyst Fibros* 2011;10: S92.
33. Conway SP, Pond MN, Hamnett T, Watson A. Compliance with treatment in adult patients with cystic fibrosis. *Thorax* 1996;51(1): 29-33.
34. Basketter HM, Sharples L, Bilton D. Knowledge of pancreatic enzyme supplementation in adult cystic fibrosis (CF) patients. *J Hum Nutr Diet* 2000;13(5):353-361.
35. Sartori R, Barbi E, Poli F, Ronfani L, Marchetti F, Amadeo A, et al. Respiratory training with a specific device in cystic fibrosis: a prospective study. *J Cystic Fibr* 2008;7(4):313-319.
36. Hollander FM, de Roos NM, Dopheide J, Hoekstra T, van Berkhout FT. Self-reported use of vitamins and other nutritional supplements in adult patients with cystic fibrosis. Is daily practice in concordance with recommendations? *Int J Vitam Nutr Res* 2010;80(6):408-415.
37. Neri L, Lucidi V, Catastini P, Colombo C. Social support, self-esteem and treatment barriers in adolescents with CF: The LINFA study. *J Cystic Fibr* 2014;13:S22.
38. McIlwaine M, Agnew J, Alarie N, Ratjen F, Lands L, Milner R, et al. Canadian national airway clearance study: patient satisfaction with positive expiratory pressure versus high frequency chest wall oscillation. *Pediatr Pulmonol* 2012;47:367.
39. Phillips AM. Home intravenous antibiotic therapy: practical aspects in adults. *J R Soc Med* 1997;90(Suppl 31):34-36.
40. Ullrich G, Bobis I, Bewig B. Perceived impact of motherhood on adherence to therapy in mothers with cystic fibrosis. *Pneumologie* 2015;69(11):673-679.
41. Wolter JM, Cagney RA, McCormack JG. A randomized trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases. *J Infect* 2004;48(3):263-268.
42. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. *Lancet* 2005;366(9484):463-471.
43. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. *Eur Resp J* 1997;10(4):896-900.
44. Kelemen L, Lee AL, Button BM, Presnell S, Wilson JW, Holland AE. Pain impacts on quality of life and interferes with treatment in adults with cystic fibrosis. *Physiother Res Int* 2012;17(3):132-141.
45. Dwyer TJ, Robbins L, Kelly P, Piper AJ, Bell SC, Bye PT. Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial. *J Physiother* 2015;61(3):142-147.
46. Kopp BT, Hayes D, Jr., Ghera P, Patel A, Kirkby S, Kowatch RA, et al. Pilot trial of light therapy for depression in hospitalized patients with cystic fibrosis. *J Affect Disord* 2016;189:164-168.
47. Kravynack NC. Coming to a definition of a pulmonary exacerbation. *Pediatr Pulmonol* 2010;45:155-157.
48. Elphick HE, Jahnke N. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. *Cochrane Database Syst Rev* 2014;4:CD002007.
49. Cushen B, McKenna S, Nicholson T, McKone EF, Gallagher CG. Day to day variability of symptoms in patients with cystic fibrosis during periods of clinical stability. *Irish J Med Sci* 2011;180:S441.
50. Dentice RL, Elkins MR, Middleton PG, Bishop JR, Wark PA, Dorahy DJ, et al. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis. *Thorax* 2016;71(2): 141-147.
51. Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. *Qual Life Res* 2012;21(7): 1267-1278.
52. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. *Eur J Cancer* 1994;30A(9):1326-1336.



53. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. *Chest* 2005;128(4):2347-2354.
54. Quon BS, Patrick DL, Edwards TC, Aitken ML, Gibson RL, Genatossio A, et al. Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state. *J Cyst Fibros* 2012;11(3):216-222.
55. Quittner AL. Measurement of quality of life in cystic fibrosis. *Curr Opin Pulm Med* 1998;4(6):326-331.
56. Wojewodka G, De Sanctis JB, Bernier J, Berube J, Ahlgren HG, Gruber J, et al. Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients. *PloS One* 2014;9(2):e88567.
57. West NE. The stop trial: An observational pilot and feasibility study of exacerbation management. *Pediatr Pulmonol* 2015;50:124-126.
58. Demars N, Sullivan K, Barnico K, Sawicki G. Patient-reported outcomes & satisfaction with a home intravenous antibiotic program for cystic fibrosis exacerbations. *Pediatr Pulmonol* 2010;45:369-370.
59. Quittner AL, Modi AC, Wainwright C, Otto K, Kiriara J, Montgomery AB. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic *Pseudomonas aeruginosa* airway infection. *Chest* 2009;135(6):1610-1618.
60. Bennett AV, Patrick DL, Lymp JF, Edwards TC, Goss CH. Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis. *J Cyst Fibros* 2010;9(6):419-424.
61. Kaeppli S. Man muss sich immer wieder neu einstellen: mit cystischer fibrose leben. Bern: Schweizerische Gesellschaft für Gesundheitspolitik (SGGP), 2013.
62. Lopez V, Copp G, Brunton L, Molassiotis A. Symptom experience in patients with gynecological cancers: the development of symptom clusters through patient narratives. *J Support Oncol* 2011;9(2):64-71.
63. Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, et al. Development of the EXacerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. *Value Health* 2010;13(8):965-975.
64. Leidy NK, Murray LT, Monz BU, Nelsen L, Goldman M, Jones PW, et al. Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials. *Respir Res* 2014;15:124.
65. Selby D, Chakraborty A, Myers J, Saskin R, Mazzotta P, Gill A. High scores on the Edmonton Symptom Assessment Scale identify patients with self-defined high symptom burden. *J Palliat Med* 2011;14(12):1309-1316.